HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and maintained a $41 price target.
April 26, 2024 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reiterates a Buy rating on Syndax Pharmaceuticals with a $41 price target.
The reiteration of a Buy rating and maintenance of a $41 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards SNDX. This endorsement reaffirms the firm's confidence in the company's prospects, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100